Health economic evaluation of implementing a universal immunization program with nirsevimab compared to standard of care for the prevention of respiratory syncytial virus disease in Canadian infants

Respiratory syncytial virus (RSV) is a highly contagious pathogen and a leading cause of severe lower respiratory tract illness (LRTI) in infants and young children, irrespective of risk factors. Nirsevimab, an extended half-life monoclonal antibody, was approved in Canada in 2023 as a passive immun...

Full description

Bibliographic Details

Published in:	Human Vaccines & Immunotherapeutics
Main Authors:	Thomas Shin, Jason Kh Lee, Alexia Kieffer, Michael Greenberg, Jianhong Wu
Format:	Article
Language:	English
Published:	Taylor & Francis Group 2025-12-01
Subjects:	Respiratory syncytial virus (RSV) nirsevimab infants Canada cost-effectiveness health economics
Online Access:	https://www.tandfonline.com/doi/10.1080/21645515.2025.2480875